



Luspatercept Increases Hemoglobin, Reduces Liver Iron Concentration and Improves Quality of Life in Non-Transfusion Dependent Adults with Beta-Thalassemia

Antonio G. Piga, MD¹, Silverio Perrotta, MD², Angela Melpignano, MD³, Caterina Borgna-Pignatti, MD⁴, M. Rita Gamberini, MD⁴, Ersi Voskaridou, MD⁵, Vincenzo Caruso, MD⁶, Paolo Ricchi, MD⁷, Antonello Pietrangelo, MD⁸, Xiaosha Zhang⁹, Dawn M. Wilson⁹, Ashley Bellevue⁹, Abderrahmane Laadem, MD¹⁰, Matthew L. Sherman, MD⁹ and Kenneth M. Attie, MD⁹
¹Turin University, Turin ²Second University of Naples, Naples, ³Ospedale "A. Perrino", Brindisi, ⁴Arcispedale S. Anna, Cona, Ferrara, Italy; ⁵Laiko General Hospital, Athens, Greece; ⁶ARNAS Garibaldi, Catania, ⁷AORN "A. Cardarelli", Naples, Italy; ⁸CEMEF, Medicina 2, Modena, Italy; ⁹Acceleron Pharma, Cambridge, MA, USA; ¹⁰Celgene Corporation, Summit, NJ, USA.



Introduction


- β-thalassemia is an inherited anemia due to defective synthesis of β-globin
 - Excess unpaired α-globin chains lead to ineffective erythropoiesis characterized by apoptosis of maturing erythroblasts in the bone marrow
- Excess GDF11 and other TGF-β superfamily ligands increase Smad 2/3 signaling and block RBC maturation, resulting in erythroid hyperplasia in the bone marrow



- Luspatercept is an investigational drug that is a recombinant fusion protein containing a modified extracellular domain (ECD) of the activin receptor type IIB (ActRIIB)
- Luspatercept binds to GDF11 and other ligands, inhibits Smad 2/3 signaling, and promotes late-stage erythroid differentiation¹
- Luspatercept increased hemoglobin levels in healthy volunteers² and patients with myelodysplastic syndromes³

Non-Clinical Studies

- RAP-536 (murine luspatercept) reduces ineffective erythropoiesis and disease burden in mouse model of β-thalassemia^{4,5}



Methods

- This is an ongoing, Phase 2, multicenter, open-label study in adults with β-thalassemia (data as of 11Mar2016)
 - Non-transfusion dependent (NTD): < 4 units/8 wk, Hb < 10 g/dL
 - Transfusion dependent (TD): ≥ 4 units/8 wk
- Primary efficacy endpoints (over 8 or 12 wk)
 - NTD: Hemoglobin increase ≥ 1.0 or ≥ 1.5 g/dL
 - TD: Transfusion burden decrease ≥ 20% or ≥ 50%
- Secondary endpoints include:
 - Safety, liver iron concentration (LIC, by MRI), health-related quality of life (FACT-An), biomarkers
- Data for TD patients are presented separately

Study Design

- Dose levels (SC q3 weeks)
 - Base study dose escalation phase (n=35): 0.2, 0.4, 0.6, 0.8, 1.0, and 1.25 mg/kg and expansion cohort (n=29): starting dose 0.8 mg/kg, titration up to 1.25 mg/kg (total n=64)
 - Extension study (n=51): 0.8-1.25 mg/kg
- Follow-up
 - All patients are followed for 2 months post treatment completion or early discontinuation

Base Study (n=64)
3 Months
NCT01749540

Extension Study (n=51)
→ 2 years (ongoing)
NCT02258409

NTD: n=34

- n=12 lower dose levels (0.2-0.4)
- n=22 higher dose levels (≥ 0.6)

NTD: n=27

- higher dose levels

NTD Patients: Baseline Characteristics


Parameter	Base Study N=34	Extension Study N=27
Age, yr, median (range)	38.5 (20-62)	37 (23-62)
Sex, male, n (%)	21 (62%)	17 (63%)
Splenectomy, n (%)	23 (68%)	18 (67%)
Hemoglobin, g/dL, median (range)	8.5 (6.5-9.8)	8.7 (7.6-9.8)
LIC, mg/g dry wt, mean ± SD	5.5 ± 3.8	4.9 ± 3.4

LIC: liver iron concentration (by MRI)

NTD Patients: Hemoglobin Change


Hemoglobin response over a 12 wk period vs baseline	Patients Treated with ≥ 0.6 mg/kg with Hb Response, n (%)	
	Base Study N=22	Extension Study N=27
Increase in mean Hb ≥ 1.0 g/dL	14 (64%)	21 (78%)
Increase in mean Hb ≥ 1.5 g/dL	8 (36%)	15 (56%)

- Sustained increase in hemoglobin with long term treatment
- Median time to response was 8 days
- Duration of response (change in Hb ≥ 1.0 g/dL) ranged from 113 to 505+ days



NTD Patients: Quality of Life Assessments


- FACT-F is a 13-question patient-reported outcome (PRO) questionnaire (subscore of FACT-An) used to assess anemia related symptoms (e.g., fatigue)
- 9/13 (69%) patients with baseline deficit (<44) improved by ≥ 3 points (proposed minimal clinically important difference) at 24 wks (last observation carried forward)
- Increase in mean hemoglobin over a 12-wk period correlated with increase in FACT-F (r=0.67, p=0.001)



- Hb 12 wk Change ≥ 1.0 g/dL
- Hb 12 wk Change < 1.0 g/dL

NTD Patients: Liver Iron Concentration (MRI)

- 60% (3/5) of patients treated for ≥ 6 months with baseline LIC ≥ 5 had decrease in LIC ≥ 2 mg/g dw
- 89% (8/9) patients with baseline LIC < 5 maintained LIC < 5 mg/g dw



Safety Results

- No related serious adverse events in either study
- One grade 3 related adverse event of headache (n=1, extension)
- Reasons for discontinuation in NTD patients included non-compliance (n=2) and prohibited medication, headache, bone pain, lost to follow-up, and patient request (n=1 each)

Preferred Term	Patients with Related AEs (all grades) in > 10% NTD Patients, n (%)	
	NTD Patients N=34	Overall N=64
Bone pain	9 (27%)	24 (38%)
Headache	9 (27%)	16 (25%)
Musculoskeletal pain	6 (18%)	10 (16%)
Arthralgia	5 (15%)	13 (20%)

Summary/Conclusions

- Luspatercept was generally safe and well-tolerated
- Sustained hemoglobin increase was observed in the majority of NTD patients in the higher dose groups and correlated with an improvement in Quality of Life
- Reductions in liver iron concentration were also observed
- These results support further investigation of luspatercept in patients with non-transfusion dependent β-thalassemia
- A Phase 3 study of luspatercept in regularly transfused patients with β-thalassemia is currently enrolling patients (The BELIEVE Study; NCT02604433)

References

- Suragani R et al., Nature Med 2014
- Attie, K et al., Am J Hematol 2014
- Platzbecker U et al., EHA 2016 abstract S131
- Suragani R et al., Blood, 2014
- Martinez P et al., EHA 2016 abstract S136

